Graves Disease (Overactive Thyroid) Market By Treatment (Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Ph

Graves Disease (Overactive Thyroid) Market By Treatment (Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Graves' disease, also known as toxic diffuse goiter, is an autoimmune disease that results in overproduction of thyroid hormones (hyperthyroidism). It is the most common cause of hyperthyroidism. Graves' disease develops when the immune system makes antibodies that stimulate the thyroid gland to grow and produce excess thyroid hormones. Excess thyroid hormones causes speeding up of many of the body's functions. Common symptoms of Graves' disease include tremors, anxiety, weight loss, heart palpitations, and heat intolerance. Graves' disease affects about 0.5% of the general population, although the disease is more common in women. The disease is believed to have a genetic component, and often runs in families. Although it is not curable, Graves' disease can be effectively treated by antithyroid medications, radioactive iodine therapy, or surgery to remove part or all of the thyroid gland.

Market Dynamics:

Global graves’ disease (overactive thyroid) market growth is driven by factors like growing aging population and increasing prevalence of thyroid disorders. According to American Thyroid Association, Graves' disease affects about 0.5% of the population in the U.S. every year. Increasing healthcare expenditure, availability of newer treatment options, and rising awareness about disease diagnosis and management can also drive the market growth. However, side effects associated with antithyroid medications such as weight gain, hair loss and liver damage can hinder the market growth. High costs involved in surgeries and radioactive iodine therapy can also hamper the market growth. Ongoing drug innovations and clinical trials on newer drug molecules and combination therapies can offer lucrative opportunities for market growth over the forecast period.

Key Features of the Study:

• This report provides in-depth analysis of the global graves’ disease (overactive thyroid) market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global graves’ disease (overactive thyroid) market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., Pfizer Inc., RLC LABS, Inc., Merck KGaA, Eisai Co., Ltd., Novartis AG, Mylan N.V., Aspen Pharmacare Holdings Limited, Sanofi, GlaxoSmithKline plc, AstraZeneca, Horizon Therapeutics plc, Alara Pharmaceutical Corporation, Antares Pharma, Inc., Apitope Technology (Bristol) Ltd., IONIS Pharmaceuticals, Inc., Immunovant, Inc., HanAll Biopharma Co., Ltd., Cara Therapeutics
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global graves’ disease (overactive thyroid) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global graves’ disease (overactive thyroid) market

Detailed Segmentation-

• By Treatment
• Anti-thyroid Drugs
• Beta Blockers
• Iodine Therapy
• Radioactive Iodine Therapy
• Others
• By Route of Administration
• Oral
• Parenteral
• Others
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• AbbVie Inc.
• Pfizer Inc.
• RLC LABS, Inc.
• Merck KGaA
• Eisai Co., Ltd.
• Novartis AG
• Mylan N.V.
• Aspen Pharmacare Holdings Limited
• Sanofi
• GlaxoSmithKline plc
• AstraZeneca
• Horizon Therapeutics plc
• Alara Pharmaceutical Corporation
• Antares Pharma, Inc.
• Apitope Technology (Bristol) Ltd.
• IONIS Pharmaceuticals, Inc.
• Immunovant, Inc.
• HanAll Biopharma Co., Ltd.
• Cara Therapeutics